Form 4: IMMUNIC CEO Granted 6 Million Stock Appreciation Rights

IMMUNIC, Inc. CEO Daniel Vitt was granted 6.02 million Stock Appreciation Rights with an exercise price of $0.77, contingent on future corporate actions and shareholder approval.

Summary

• Daniel Vitt, CEO and Director of IMMUNIC, INC. (IMUX), was granted a total of 6,020,000 Stock Appreciation Rights (SARs) on July 16, 2025.
• Each SAR has an exercise price of $0.77 and is intended to be settled in shares of the Issuer's common stock, subject to stockholder approval to amend the 2019 Omnibus Equity Incentive Plan.
• The SARs become exercisable starting August 1, 2026, and will expire on July 16, 2035.
• Exercisability is contingent on the exercise of the Issuer's Series A and Series B purchase warrants by holders.
• Exercisability is also contingent on the Issuer's issuance of Common Stock or pre-funded warrants related to the second and third tranches of the January 4, 2024 private placement.

Sentiment

Score: 7

Explanation: The grant of significant equity compensation to the CEO is generally positive as it aligns management's interests with shareholder value. However, the contingent nature of exercisability and potential future dilution introduce some uncertainty.

Positives

• The grant of significant equity compensation to CEO Daniel Vitt aligns management's interests with shareholder value creation, as the SARs' value is tied to the company's stock performance.
• The SARs have a long expiration date of July 16, 2035, providing a long-term incentive for the CEO.

Negatives

• Potential future dilution for existing shareholders if the SARs are settled in common stock and the necessary stockholder approval is obtained.
• The exercisability of the SARs is subject to several future conditions, including warrant exercises and completion of private placement tranches, which introduces uncertainty regarding their ultimate value and timing.

Risks

• Dilution Risk: If the SARs are settled in shares, it could lead to dilution for existing shareholders, contingent on stockholder approval of the 2019 Omnibus Equity Incentive Plan amendment.
• Contingency Risk: The exercisability of the SARs is subject to the exercise of Series A and Series B purchase warrants and the completion of the second and third tranches of the January 2024 private placement, which may not occur as planned.
• Market Price Risk: The value of the SARs is dependent on the future market price of IMMUNIC's common stock exceeding the $0.77 exercise price; if the stock price does not rise above this level, the SARs may hold no intrinsic value.

Future Outlook

The company intends to settle the granted Stock Appreciation Rights in shares of common stock, contingent on obtaining stockholder approval to amend its 2019 Omnibus Equity Incentive Plan. The exercisability of these SARs is also tied to future events, including the exercise of Series A and B purchase warrants and the completion of subsequent tranches of the January 2024 private placement.

Management Comments

• Daniel Vitt, CEO and Director, filed the Statement of Changes in Beneficial Ownership (Form 4) reporting the acquisition of Stock Appreciation Rights.
• The Issuer intends for the Stock Appreciation Rights to be settled in shares of common stock, subject to stockholder approval to amend the 2019 Omnibus Equity Incentive Plan.

Industry Context

This filing is a standard disclosure of executive equity compensation, a common practice in the biotechnology and pharmaceutical industries (given IMUX ticker) to align management incentives with long-term company performance and shareholder value. The reliance on private placements and warrants for financing is also typical for development-stage biotech companies.

Comparison to Industry Standards

• While specific comparable companies or projects are not detailed in this Form 4, the grant of Stock Appreciation Rights to a CEO is a common form of long-term incentive compensation in the biotechnology sector.
• The size of the grant (6.02 million SARs) would typically be evaluated against peer company compensation structures, market capitalization, and the company's stage of development.
• The conditions tied to warrant exercises and private placement tranches are specific to IMMUNIC's financing strategy and reflect its current capital structure and funding needs.

Corporate Governance

Related Party Transactions

• The grant of 6,020,000 Stock Appreciation Rights to Daniel Vitt, the CEO and Director, constitutes a related party transaction as it involves compensation to a key executive.

Stakeholder Impact

• Shareholders: Potential for future dilution if SARs are settled in shares, but also benefit from aligned management incentives. Required to vote on the plan amendment.
• Employees: The 2019 Omnibus Equity Incentive Plan, which is being amended, affects the broader employee equity compensation framework.
• Management (Daniel Vitt): Receives significant long-term incentive compensation tied to the company's stock performance and future financing activities.

Next Steps

• Obtain stockholder approval to amend the 2019 Omnibus Equity Incentive Plan to allow for sufficient shares to settle the SARs in common stock.
• Completion of the exercise of the Issuer's Series A and Series B purchase warrants by holders.
• Completion of the second and third tranches of the January 2024 private placement, involving the issuance of Common Stock or pre-funded warrants.
• SARs become exercisable on August 1, 2026, subject to stated conditions.

Key Dates

Keywords

IMMUNIC, IMUX, Daniel Vitt, Stock Appreciation Rights, SARs, equity compensation, insider ownership, SEC Form 4, executive compensation, private placement, warrants, corporate governance